Soft Tissue Biologics Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

PUBLISHED: October 18, 2024

PAGES: 55 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

GlobalData's Medical Devices sector report, "Soft Tissue Biologics Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Soft Tissue Biologics pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Soft Tissue Biologics are used in surgical procedures to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. Soft Tissue Biologics market focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles's tendon.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Soft Tissue Biologics under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Soft Tissue Biologics and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Soft Tissue Biologics under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date

Product Code: GDME1862EPD

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 Soft Tissue Biologics Overview

3 Products under Development

3.1 Soft Tissue Biologics - Pipeline Products by Stage of Development
3.2 Soft Tissue Biologics - Pipeline Products by Segment
3.3 Soft Tissue Biologics - Pipeline Products by Territory
3.4 Soft Tissue Biologics - Pipeline Products by Regulatory Path
3.5 Soft Tissue Biologics - Pipeline Products by Estimated Approval Date
3.6 Soft Tissue Biologics - Ongoing Clinical Trials

4 Soft Tissue Biologics - Pipeline Products under Development by Companies

4.1 Soft Tissue Biologics Companies - Pipeline Products by Stage of Development
4.2 Soft Tissue Biologics - Pipeline Products by Stage of Development

5 Soft Tissue Biologics Companies and Product Overview

5.1 Acuitive Technologies Inc Company Overview
- 5.1.1 Acuitive Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Anika Therapeutics Inc Company Overview
- 5.2.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.3 BioGend Therapeutics Co Ltd Company Overview
- 5.3.1 BioGend Therapeutics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.4 Colorado Therapeutics, LLC Company Overview
- 5.4.1 Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.5 Columbia University Company Overview
- 5.5.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
5.6 Core Essence Orthopaedics, LLC Company Overview
- 5.6.1 Core Essence Orthopaedics, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.7 Georgia Institute of Technology Company Overview
- 5.7.1 Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview
5.8 New York R&D Center for Translational Medicine and Therapeutics Inc Company Overview
- 5.8.1 New York R&D Center for Translational Medicine and Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.9 Nutech Medical Inc Company Overview
- 5.9.1 Nutech Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.10 OHSU Knight Cancer Institute Company Overview
- 5.10.1 OHSU Knight Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview
5.11 Osteopore International Pte Ltd Company Overview
- 5.11.1 Osteopore International Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.12 Shandong Junxiu Biotechnology Co Ltd Company Overview
- 5.12.1 Shandong Junxiu Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.13 STEL Technologies LLC Company Overview
- 5.13.1 STEL Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview
5.14 Tissue Regenix Group PLC Company Overview
- 5.14.1 Tissue Regenix Group PLC Pipeline Products & Ongoing Clinical Trials Overview
5.15 University of Arizona Company Overview
- 5.15.1 University of Arizona Pipeline Products & Ongoing Clinical Trials Overview
5.16 University of Bielefeld Company Overview
- 5.16.1 University of Bielefeld Pipeline Products & Ongoing Clinical Trials Overview
5.17 University of Minnesota Company Overview
- 5.17.1 University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview
5.18 University of Missouri Company Overview
- 5.18.1 University of Missouri Pipeline Products & Ongoing Clinical Trials Overview
5.19 University of Zurich Company Overview
- 5.19.1 University of Zurich Pipeline Products & Ongoing Clinical Trials Overview

6 Soft Tissue Biologics- Recent Developments

6.1 Aug 27, 2024: Chinese Academy of Sciences : 3D Bioprinting Materials Offer Possibility for Better Bone and Soft Tissue Repair
6.2 Aug 12, 2024: Biorez Receives 510(K) Clearance for BioBrace Reinforced Implant
6.3 Jun 11, 2024: Allosource Launches Aceconnex, First Pre-sutured Fascia Device for Hip Labral Reconstruction and Augmentation
6.4 May 02, 2024: Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
6.5 Nov 02, 2023: Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023
6.6 Oct 31, 2023: BioTissue's Innovative Human Amniotic Allografts Show Efficacy in Treating Complex Foot Ulcers and Traumatic Wounds in Case Studies